Do Not Throw In Towel On Biosimilars, Says New Sandoz Chief

Assertions that the US should give up on supporting biosimilars in favor of controlling prices of off-patent biologic brands fail to recognize promising signs of progress, argues Richard Saynor, who has just taken over as CEO of biosimilars pioneer Sandoz.